In hepatocellular carcinoma, an oncogenic EGF-EGFR-PI3K/Akt pathway was shown to increase p300 HAT-mediated H3K9 acetylation of the HMGA2 promoter, resulting in higher HMGA2 gene expression and a poor prognosis [79]. This evidence concerns the gene EGFR and hepatocellular carcinoma.